EMA’s reflection paper on AI in the pharmaceutical lifecycle by Giuliana Miglierini The rapidly evolving role of artificial intelligence (AI) and its possible application in the pharmaceutical…
EMA, new features for the PRIority Medicines (PRIME) scheme By Giuliana Miglierini Based on the review of results obtained in the first five years of implementation of…
A new joint work plan to 2023 for EMA and EUnetHTA 21 by Giuliana Miglierini The new Regulation (EU) 2021/228 on Health Technology Assessment (HTA) will assume full validity in…